28. Dahl f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbid- ity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995 1003. 29. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for preven- tion of cardiovascular disease and death: a systematic review and meta- analysis. Lancet. 2016;387:957 67. 30. Guo X, Zhang X, Guo L, et al. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of pro- spective studies. Curr Hypertens Rep. 2013;15:703 16. 31. Guo X, Zhang X, Zheng L, et al. Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS ONE. 2013;8:e61796. 32. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta- analysis. Neurology. 2014;82:1153 61. 33. Huang Y, Cai X, Liu C, et al. Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis. J Am Heart Assoc. 2015;4:e001519. 34. Huang Y, Cai X, Zhang J, et al. Prehypertension and incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63:76 83. 35. Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovascular mor- tality with prehypertension: a meta-analysis. Am Heart J. 2014;167:160 168.e1. 36. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardio- vascular disease: a meta-analysis. BMC Med. 2013;11:177. 37. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised tri- als in the context of expectations from prospective epidemiological stud- ies. BMJ. 2009;338:b1665. 38. Lee M, Saver JL, Chang B, et al. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. Neurology. 2011;77:1330 7. 